Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Time-weighted ctDNA dynamics for precision monitoring of relapse risk in colon cancer.

Alessandro Leal, Madeline Rose Miceli, Dalia Littman et al. Jun 01, 2025 pp. 3608-3608 10.1200/jco.2025.43.16_suppl.3608

3608 Background: Effective monitoring for relapse is a critical component of post-surgical care in colorectal cancer (CRC), particularly for patients who...

The evolving landscape of academic and industry partnerships in gynecologic oncology clinical trials.

Kevin Ji Li, Qiao Ruan, Nathan Tran et al. Jun 01, 2025 pp. 9038-9038 10.1200/jco.2025.43.16_suppl.9038

9038 Background: To determine trends in the financial relationships of study investigators in gynecologic oncology trials. Methods:...

Demographic and clinical factors associated with young-onset rectal cancer: Is the Latinx population at higher risk?

Antoine Jeri-Yabar, Liliana Vittini, Marcos Rosa Santana et al. Jun 01, 2025 pp. 11038-11038 10.1200/jco.2025.43.16_suppl.11038

11038 Background: The incidence of colorectal cancer is rising among younger adults, with some studies indicating a disproportionate increase in the Hispa...

Prevalence of histology-agnostic biomarkers in pure squamous cell carcinomas of the genitourinary tract.

Saad Omar Atiq, Dilara Akbulut, Shayan S. Nazari et al. Jun 01, 2025 pp. 4609-4609 10.1200/jco.2025.43.16_suppl.4609

4609 Background: Pure squamous cell carcinomas (SCC) of the genitourinary (GU) tract are less responsive to chemotherapy with limited therapeutic options...

Effect of branched-chain amino acid metabolic interactions between HIBADH+ tumor cells and BCAT1+ macrophages on immunotherapy response in advanced NSCLC.

Zhe Wu, Yuanyuan Wang, Min Shi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20601

e20601 Background: Tumor immune checkpoint inhibitors (ICIs) have been established as the first-line standard treatment for advanced NSCLC with negative d...

Impact of body mass index on immunotherapy outcomes and complications in solid tumor patients: A real-world evidence analysis.

Moath Albliwi, Rahaf Yaghi, Basil Jalamneh et al. Jun 01, 2025 pp. 2603-2603 10.1200/jco.2025.43.16_suppl.2603

2603 Background: Obesity alters immune function by modifying cytokine profiles and altering immune cells. Body mass index (BMI) influences cancer outcomes...

Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced, metastatic gastroesophageal adenocarcinoma: The phase 3, randomized LEAP-015 study.

Kohei Shitara, Sylvie Lorenzen, Yuxian Bai et al. Jun 01, 2025 pp. 4001-4001 10.1200/jco.2025.43.16_suppl.4001

4001 Background: LEAP-015 (NCT04662710), is a randomized, open-label, phase 3 study of pembrolizumab plus lenvatinib and chemotherapy as first-line treatm...

Randomized control trial to validate mitigation of chemotherapy-induced peripheral neuropathy by limb-cooling apparatus in breast cancer patients receiving paclitaxel (CECILIA).

Toshimi Takano, Chikako Funasaka, Nobuaki Matsubara et al. Jun 01, 2025 pp. 12002-12002 10.1200/jco.2025.43.16_suppl.12002

12002 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event affecting patient quality of life. Limb cooling may help to...

Early signals of Inflation Reduction Act impact on small-molecule versus biologic post-approval oncology trials.

Hanke Zheng, Julie Patterson, Jonathan D. Campbell Jun 01, 2025 pp. 11032-11032 10.1200/jco.2025.43.16_suppl.11032

11032 Background: The Inflation Reduction Act’s Drug Price Negotiation Program (DPNP) has shifted the financial incentives for post-approval clinical deve...

Assessment of PSMA PET/CT derived predictive markers for <sup>177</sup> Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program.

Koichiro Kimura, Vishnu Murthy, Andrew F. Voter et al. Jun 01, 2025 pp. 5079-5079 10.1200/jco.2025.43.16_suppl.5079

5079 Background: 177 Lu-PSMA-617 (Lu-PSMA) contributes to prolong progression-free survival (PFS) and overall survival (OS) in metastatic cast...

The impact of firstline immunotherapy and tyrosine kinase inhibitors combinations versus sunitinib on clinical outcomes of favorable risk advanced renal cell carcinoma: A meta-analysis of randomized studies.

Ankita Gupta, Jamie Lee Aldakkour, Sireesha Vutukuri et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16504

e16504 Background: Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, with clear cell carcinoma being the predominant histolog...

Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors.

Thomas Urban Marron, Zev A. Wainberg, Alexander I. Spira et al. Jun 01, 2025 pp. 2577-2577 10.1200/jco.2025.43.16_suppl.2577

2577 Background: ENPP1 clears cGAMP and ATP in the tumor microenvironment (TME). Its expression is associated with poor prognosis in cancer and developmen...

The global and regional burden of breast cancer in females from 1990-2023: A systematic analysis for the Global Burden of Disease study 2023.

Kayleigh Bhangdia, Alistair Acheson, Andrew Crist et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22575

e22575 Background: Breast cancer is one of the most common cancers globally with approximately one in eight females developing breast cancer in their life...

Assessment of long-term toxicities of imatinib in CML: Experience from a tertiary care cancer centre in south India.

Akhil Santhosh, Prasanth V. Parameswaran, Sreedharan P.S. et al. Jun 01, 2025 pp. 6564-6564 10.1200/jco.2025.43.16_suppl.6564

6564 Background: Imatinib has been the standard 1 st line drug for chronic myeloid leukemia (CML) in chronic phase for decades. Li...

Comparative efficacy of adjuvant FOLFOX versus FLOT following neoadjuvant FLOT in locally advanced gastric cancer.

Furkan Ceylan, Didem Şener Dede, Safa Can Efil et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16120

e16120 Background: Perioperative FLOT is the gold-standard treatment for locally advanced gastric cancer (LAGC). However, the tolerability of adjuvant che...

The prognostic impact of TP53 mutation on survival outcomes in ALK fusion–positive lung cancer.

Yash Rakesh Shah, Minit Jalan Shah, Vanita Noronha et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20651

e20651 Background: Patients with advanced anaplastic lymphoma kinase (ALK) rearranged lung adenocarcinoma have better survival outcomes when treated with...

A phase II study of perioperative intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.

Brian D. Badgwell, Naruhiko Ikoma, Mariela A. Blum Murphy et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4210

TPS4210 Background: Over the last 2 decades, intraperitoneal chemotherapy has been found to have activity for select subgroups of patients with carcinomat...

The state of the oncologist workforce in America in areas prone to natural disasters.

M. Kelsey Kirkwood, Manali I. Patel, Erin P. Balogh et al. Jun 01, 2025 pp. 11084-11084 10.1200/jco.2025.43.16_suppl.11084

11084 Background: Natural disasters are increasingly common in the U.S., causing significant localized disruptions to cancer care. The American Society of...

Clinicopathologic characteristics and survival outcomes in adolescent and young adults with breast cancer.

Madeleine Turcotte, Cody Lebeck Lee, Margaret Comer et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12508

e12508 Background: Breast cancer is the most common cancer and the leading cause of cancer-related death among adolescent and young adults (AYA) diagnosed...

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER 2+ breast cancer in Morocco.

Rhizlane Belbaraka, Mouna Bourhafour, Lamya Amaadour et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13008

e13008 Background: Trastuzumab (TZM) is available in IV (intravenous) and SC (subcutaneous) formulations in Morocco and is indicated for the treatment of...

Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER).

Andrew J. Wagner, Silvia Stacchiotti, Channa Debruyne et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps11582

TPS11582 Background: Conventional chondrosarcoma (CS) is the most common chondrosarcoma subtype, accounting for 85% to 90%...

Psychological interventions for anxiety in older patients with lung cancer: A systematic review.

Eleanor Xu, Michael A. Liu Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24046

e24046 Background: Lung cancer is the leading cause of death among cancer types and primarily occurs among older adults. Anxiety in older adults tends to...

MRI radiomics to predict outcome of neoadjuvant chemotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy.

Lawrence Howard Schwartz, Oguz Akin, Samuel Gold et al. Jun 01, 2025 pp. 4581-4581 10.1200/jco.2025.43.16_suppl.4581

4581 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) is the standard of care in patients with muscle-invasive bl...

Pancreatic cancer mortality trends (2018-2023): Exposing racial inequities in Michigan's cancer burden.

Mekdes Asfaw, Ayushi Garg, Pranav Chalasani et al. Jun 01, 2025 pp. 4180-4180 10.1200/jco.2025.43.16_suppl.4180

4180 Background: Pancreatic cancer remains one of the most aggressive malignancies, with Black individuals facing significantly worse outcomes and a young...

Real-world quality of life (QOL) in patients (pts) with metastatic renal cell carcinoma (mRCC) on active surveillance (AS) in the ODYSSEY prospective observational study.

Michael Roger Harrison, Jesse D. Troy, Benjamin L. Maughan et al. Jun 01, 2025 pp. 4553-4553 10.1200/jco.2025.43.16_suppl.4553

4553 Background: AS is a recognized strategy in select pts with mRCC to maximize QOL and delay potential toxicity of systemic therapy (ST); however, only...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page